These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29408377)

  • 1. The melatonin-MT1 receptor axis modulates tumor growth in PTEN-mutated gliomas.
    Ma H; Wang Z; Hu L; Zhang S; Zhao C; Yang H; Wang H; Fang Z; Wu L; Chen X
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1322-1330. PubMed ID: 29408377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MT1 and MT2 melatonin receptors play opposite roles in brain cancer progression.
    Kinker GS; Ostrowski LH; Ribeiro PAC; Chanoch R; Muxel SM; Tirosh I; Spadoni G; Rivara S; Martins VR; Santos TG; Markus RP; Fernandes PACM
    J Mol Med (Berl); 2021 Feb; 99(2):289-301. PubMed ID: 33392634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-92b regulates glioma cells proliferation, migration, invasion, and apoptosis via PTEN/Akt signaling pathway.
    Song H; Zhang Y; Liu N; Wan C; Zhang D; Zhao S; Kong Y; Yuan L
    J Physiol Biochem; 2016 Jun; 72(2):201-11. PubMed ID: 26893028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin.
    Martín V; Herrera F; Carrera-Gonzalez P; García-Santos G; Antolín I; Rodriguez-Blanco J; Rodriguez C
    Cancer Res; 2006 Jan; 66(2):1081-8. PubMed ID: 16424044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
    Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin inhibits proliferation and invasion via repression of miRNA-155 in glioma cells.
    Gu J; Lu Z; Ji C; Chen Y; Liu Y; Lei Z; Wang L; Zhang HT; Li X
    Biomed Pharmacother; 2017 Sep; 93():969-975. PubMed ID: 28724215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation.
    Jawed S; Kim B; Ottenhof T; Brown GM; Werstiuk ES; Niles LP
    Eur J Pharmacol; 2007 Mar; 560(1):17-22. PubMed ID: 17303109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
    Dey N; Crosswell HE; De P; Parsons R; Peng Q; Su JD; Durden DL
    Cancer Res; 2008 Mar; 68(6):1862-71. PubMed ID: 18339867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.
    Kawaguchi T; Yamashita Y; Kanamori M; Endersby R; Bankiewicz KS; Baker SJ; Bergers G; Pieper RO
    Cancer Res; 2006 Dec; 66(23):11331-40. PubMed ID: 17145879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of PTEN on proliferation and drug-, and radiosensitivity in malignant glioma cells.
    Inaba N; Kimura M; Fujioka K; Ikeda K; Somura H; Akiyoshi K; Inoue Y; Nomura M; Saito Y; Saito H; Manome Y
    Anticancer Res; 2011 May; 31(5):1653-8. PubMed ID: 21617223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma.
    Majuelos-Melguizo J; Rodríguez MI; López-Jiménez L; Rodríguez-Vargas JM; Martí Martín-Consuegra JM; Serrano-Sáenz S; Gavard J; de Almodóvar JM; Oliver FJ
    Oncotarget; 2015 Mar; 6(7):4790-803. PubMed ID: 25576921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of melatonin treatment in primary culture of canine mammary tumors.
    Lopes JR; Maschio LB; Jardim-Perassi BV; Moschetta MG; Ferreira LC; Martins GR; Gelaleti GB; De Campos Zuccari DA
    Oncol Rep; 2015 Jan; 33(1):311-9. PubMed ID: 25384569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
    Kinsella P; Howley R; Doolan P; Clarke C; Madden SF; Clynes M; Farrell M; Amberger-Murphy V
    Exp Cell Res; 2012 Mar; 318(5):641-52. PubMed ID: 22285130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.
    Gu G; Gao X; Hu Q; Kang T; Liu Z; Jiang M; Miao D; Song Q; Yao L; Tu Y; Pang Z; Chen H; Jiang X; Chen J
    Biomaterials; 2013 Jul; 34(21):5138-48. PubMed ID: 23582684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative genomic and proteomic analysis of high grade glioma primary cultures and matched tumor in situ.
    Howley R; Kinsella P; Buckley PG; Alcock L; Jansen M; Heffernan J; Stallings RL; Brett FM; Amberger-Murphy V; Farrell MA
    Exp Cell Res; 2012 Oct; 318(17):2245-56. PubMed ID: 22705586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetraarsenic oxide-induced inhibition of malignant glioma cell invasion in vitro via a decrease in matrix metalloproteinase secretion and protein kinase B phosphorylation.
    Gwak HS; Park MJ; Park IC; Woo SH; Jin HO; Rhee CH; Jung HW
    J Neurosurg; 2014 Dec; 121(6):1483-91. PubMed ID: 25303017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor.
    Shingu T; Yamada K; Hara N; Moritake K; Osago H; Terashima M; Uemura T; Yamasaki T; Tsuchiya M
    J Neurosurg; 2003 Jan; 98(1):154-61. PubMed ID: 12546364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
    Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
    Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.